Walleye Capital’s UroGen Pharma URGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14.1M Buy
+348,116
New +$14.9M 0.01% 993
2025
Q4
– Sell
-190,452
Closed -$3.8M – 5169
2025
Q3
$3.8M Sell
190,452
-155,710
-45% -$2.8M 0.01% 1102
2025
Q2
$4.74M Buy
+346,162
New +$3.32M 0.02% 893
2024
Q3
– Sell
-57,610
Closed -$967K – 5908
2024
Q2
$967K Buy
+57,610
New +$819K ﹤0.01% 2885
2024
Q1
– Sell
-27,218
Closed -$408K – 5920
2023
Q4
$408K Buy
+27,218
New +$353K ﹤0.01% 3108

Other funds holding URGN

Walleye Capital's URGN Position: Q3 2026 in Review

Walleye Capital opened a new position in UroGen Pharma (URGN) in Q3 2026: 348,116 shares worth $14.1M. The stake represents 0.01% of the portfolio and ranks #993 among its holdings. This is a return to the name: Walleye Capital previously reported a position in URGN as recently as Q3 2025.

Walleye Capital first reported a position in URGN in Q4 2023 and has held it in 5 quarters since. 215 funds tracked by Wall St. Rank hold URGN as of Q3 2026.

  • Walleye Capital held 348,116 shares of UroGen Pharma worth $14.1M as of Q3 2026.
  • UroGen Pharma was a new Walleye Capital position in Q3 2026.
  • UroGen Pharma made up 0.01% of Walleye Capital's portfolio in Q3 2026, its #993 holding.
  • Walleye Capital first reported a position in UroGen Pharma in Q4 2023 and has held it in 5 quarters since.
  • 215 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.